🔴 Azitra is trading 5% down with no confirmed company-specific explanation

Azitra is trading at $1.06, down 5.21%, with no confirmed company-specific announcement explaining its October 28 move.

• The October 26 release reported positive ex vivo ATR-COSF results and said initial human-study data are expected by year-end. That earlier news does not establish a reason for the decline.
• Biotech is higher, while the supplied major-index moves are nearly flat; neither provides a clear same-direction explanation for Azitra’s drop.